AmeriPath Home For Healthcare Providers Patient and Consumer Information About Us

 


July 28, 1998
AMERIPATH REPORTS 75 PERCENT NET REVENUE GROWTH FOR THE SECOND QUARTER

Riviera Beach, FL, July 28, 1998 ­ AmeriPath, Inc. (Nasdaq: PATH), a physician practice management company focused on anatomic pathology services today reported net revenue growth of 75 percent for the second quarter ended June 30, 1998, compared to the second quarter of the prior year.

Net revenue for the second quarter of 1998 was $40.8 million, compared to the second quarter of the prior year of $23.3 million, an increase of 75 percent. Same practice net revenue for the second quarter ended June 30, 1998 increased by $3.2 million or 13.8 percent over the second quarter of the prior year. The remaining increase of $14.3 million resulted from acquisitions completed subsequent to the quarter ended June 30, 1997. Income from operations for the quarter was $9.8 million, up 92 percent over the $5.1 million reported in the comparable period in 1997. Net income was $4.5 million compared to $1.7 million, before a nonrecurring charge of $1.3 million, for the same period last year. For the second quarter of 1998, net income increased to $0.22 per share, based on 20.7 million weighted average shares outstanding, compared to $0.08 per share based on 12.1 million weighted average shares outstanding for the same period of 1997.

For the first six months of 1998, AmeriPath reported net revenues of $78.8 million, an increase of 74 percent from the $45.3 million reported for the same period in 1997. Same practice net revenues for the six month period increased by $6.3 million, or 14.1 percent. Approximately 6.5 percent of the increase was attributable to the expansion of a contract with a national laboratory in Florida and 2.5 percent to the increase in Medicare reimbursement which was effective January 1, 1998. Net income for the period was $8.3 million, or $0.40 per share for the six month period, compared to $2.3 million, or $0.19 per share, for the same period in 1997. Annualized net revenue per pathologist of $1.0 million is still running slightly higher than the previous year. The weighted average number of shares outstanding for the six months ended June 30, 1998 was 20.6 million, compared to 12.0 million in the prior year.

During the first six months of 1998, AmeriPath acquired eight pathology practices expanding its market presence in Florida, Indiana, Texas, Mississippi and Wisconsin. These acquisitions, including the recently announced acquisition in San Antonio, Texas, added approximately $28 million to the Company's annual net revenue run rate.

James C. New, president and chief executive officer of AmeriPath, said "We are extremely pleased with our second quarter results and our accomplishments through the first half of 1998. AmeriPath is confident that this momentum will allow us to successfully execute our business strategy over the second half of 1998."

AmeriPath, Inc. is the nation's leading physician practice management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories and managed care organizations. The company presently operates in nine states and provides medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

.......................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursements, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.